This text of California § 24007. (24007. (Amended by Stats. 2021, Ch. 486, Sec. 9.)) is published on Counsel Stack Legal Research, covering California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
(a)The department shall determine the scope of benefits for the program, which shall include, but is not limited to, the following:
(1)Family planning related services and male and female sterilization. Family planning services for men and women include emergency and complication services directly related to the contraceptive method and followup, consultation, and referral services, as indicated, that may require treatment authorization requests.
(2)All United States Department of Health and Human Services, Federal Drug Administration-approved birth control methods, devices,
and supplies that are in keeping with current standards of practice and from which the individual may choose.
(3)Culturally and linguistically appropriate health education and counseling services, including i
Free access — add to your briefcase to read the full text and ask questions with AI
(a)
The department shall determine the scope of benefits for the program, which shall include, but is not limited to, the following:
(1)
Family planning related services and male and female sterilization. Family planning services for men and women include emergency and complication services directly related to the contraceptive method and followup, consultation, and referral services, as indicated, that may require treatment authorization requests.
(2)
All United States Department of Health and Human Services, Federal Drug Administration-approved birth control methods, devices,
and supplies that are in keeping with current standards of practice and from which the individual may choose.
(3)
Culturally and linguistically appropriate health education and counseling services, including informed consent; psychosocial and medical aspects of contraception, sexuality, fertility, pregnancy, and parenthood; infertility; reproductive health care; preconceptual and nutrition counseling; prevention and treatment of sexually transmitted infection; use of contraceptive methods, devices, and supplies; possible contraceptive consequences and followup; interpersonal communication and negotiation of relationships to assist individuals and couples in effective contraceptive method use and planning families.
(4)
A comprehensive health history, updated at the next periodic visit
(between 11 and 24 months after initial examination) that includes a complete obstetrical history, gynecological history, contraceptive history, personal medical history, health risk factors, and family health history, including genetic or hereditary conditions.
(5)
A complete physical examination on initial and subsequent periodic visits.
(6)
(A)
Home test kits for sexually transmitted diseases, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled Family PACT clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.
(B)
For purposes of
this paragraph, “home test kit” means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow
individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.
(C)
Reimbursement under this subparagraph shall be contingent upon the addition of codes specific to home test kits in the Current Procedural Terminology or Healthcare Common Procedure Coding System to comply with Health Insurance Portability and Accountability Act requirements. The home test kit shall be sent by the enrolled Family PACT provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.
(D)
This paragraph shall be implemented only to the extent that federal financial
participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.
(b)
Benefits under this program shall be effective in 30 days after notice to providers, but not sooner than January 1, 1997.